Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TET2 | Q6N021 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | TET3 | O43151 | 1/20 | 0.32 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methacrylic Acid SCHEMBL148580 | 1.00 | TDP1 (0.44) | TDP1OR51E2TGFBR1FFAR3LCK | |
| Methacrylic Acid SCHEMBL7638155 | 0.97 | TDP1 (0.42) | TDP1OR51E2TGFBR1FFAR3LCK | |
| Methacrylic Acid SCHEMBL29242669 | 0.94 | TDP1 (0.40) | TDP1OR51E2TGFBR1FFAR3LCK | |
| Methacrylic Acid SCHEMBL10650079 | 0.94 | TDP1 (0.40) | TDP1OR51E2TGFBR1FFAR3LCK | |
| Methacrylic Acid SCHEMBL11231005 | 0.94 | TDP1 (0.40) | TDP1OR51E2TGFBR1FFAR3LCK | |
| Methacrylic Acid SCHEMBL11035054 | 0.94 | TDP1 (0.40) | TDP1OR51E2TGFBR1FFAR3LCK | |
| Methacrylic Acid SCHEMBL8424558 | 0.91 | FFAR3 (0.41) | TDP1OR51E2TGFBR1FFAR3LCK | |
| Methacrylic Acid SCHEMBL27907841 | 0.91 | OR51E2 (0.38) | TDP1OR51E2TGFBR1FFAR3LCK | |
| Methacrylic Acid SCHEMBL3171148 | 0.91 | OR51E2 (0.38) | TDP1OR51E2TGFBR1FFAR3LCK | |
| Methacrylic Acid SCHEMBL393971 | 0.90 | TDP1 (0.42) | TDP1OR51E2TGFBR1FFAR3LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7275933-B2 | Method of manufacturing dental restorations | PENTRON CLINICAL TECHNOLOGIES, LLC (US) | 2007-10-02 | — | — | US | claimed |
| US-20040249015-A1 | Method of manufacturing dental restorations | KERR CORPORATION | 2004-12-09 | — | — | US | claimed |
| US-6787584-B2 | BIODEGRADABLE MACROMONOMER HAVING TERMINAL ACRYLATE OR METHACRYLATE GROUP(S) (ACRYLATED POLYLACTONE); A CURING COMPOSITION; A FILLER OF BIOACTIVE GLASS, APATITES, AND OTHER (METH)ACRYLATES | PENTRON CORPORATION | 2004-09-07 | — | — | US | claimed |
| WO-2002078646-A1 | DENTAL COMPOSITIONS | PENTRON CORPORATION (US) | 2002-10-10 | — | — | WO | claimed |
| US-20020120033-A1 | Biodegradable macromonomer having terminal acrylate or methacrylate group(s) (acrylated polylactone); a curing composition; a filler of bioactive glass, apatites, and other (meth)acrylates | KERR CORPORATION | 2002-08-29 | — | — | US | claimed |
| EP-1202701-A1 | DENTAL COMPOSITIONS COMPRISING DEGRADABLE POLYMERS | JENERIC/PENTRON Incorporated (US) | 2002-05-08 | — | — | EP | claimed |
| WO-2001012129-A1 | DENTAL COMPOSITIONS COMPRISING DEGRADABLE POLYMERS | JENERIC/PENTRON INCORPORATED (US) | 2001-02-22 | — | — | WO | claimed |
| US-7855242-B2 | Dental resin composition, method of manufacture, and method of use thereof | PENTRON CLINICAL TECHNOLOGIES LLC (US) | 2010-12-21 | — | — | US | disclosed |
| US-7275933-B2 | Method of manufacturing dental restorations | PENTRON CLINICAL TECHNOLOGIES, LLC (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070049656-A1 | DENTAL RESIN COMPOSITION, METHOD OF MANUFACTURE, AND METHOD OF USE THEREOF | PENTRON CLINICAL TECHNOLOGIES, INC (US) | 2007-03-01 | — | — | US | disclosed |
| US-20040249015-A1 | Method of manufacturing dental restorations | KERR CORPORATION | 2004-12-09 | — | — | US | disclosed |
| US-6787584-B2 | BIODEGRADABLE MACROMONOMER HAVING TERMINAL ACRYLATE OR METHACRYLATE GROUP(S) (ACRYLATED POLYLACTONE); A CURING COMPOSITION; A FILLER OF BIOACTIVE GLASS, APATITES, AND OTHER (METH)ACRYLATES | PENTRON CORPORATION | 2004-09-07 | — | — | US | disclosed |
| WO-2002078646-A1 | DENTAL COMPOSITIONS | PENTRON CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |
| US-6455608-B1 | CURABLE DENTAL FORMULATION COMPRISING DEGRADABLE MACROMONOMERS HAVING ONE OR MORE TERMINAL ACRYLATE OR METHACRYLATE FUNCTIONALITY, A CURING AGENT; PREPARING A SITE TO BE RESTORED IN A TOOTH AND APPLYING ABOVE FORMULATION | JENERIC/PENTRON INCORPORATED | 2002-09-24 | — | — | US | disclosed |
| US-20020120033-A1 | Biodegradable macromonomer having terminal acrylate or methacrylate group(s) (acrylated polylactone); a curing composition; a filler of bioactive glass, apatites, and other (meth)acrylates | KERR CORPORATION | 2002-08-29 | — | — | US | disclosed |
| EP-1202701-A1 | DENTAL COMPOSITIONS COMPRISING DEGRADABLE POLYMERS | JENERIC/PENTRON Incorporated (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001012129-A1 | DENTAL COMPOSITIONS COMPRISING DEGRADABLE POLYMERS | JENERIC/PENTRON INCORPORATED (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049656-A1 | DENTAL RESIN COMPOSITION, METHOD OF MANUFACTURE, AND METHOD OF USE THEREOF | CAD, MMAB, DNMT3A | TDP1 1326/4885OR51E2 4204/4885TGFBR1 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.